These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16272333)

  • 1. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
    Renckens R; Roelofs JJ; ter Horst SA; van 't Veer C; Havik SR; Florquin S; Wagenaar GT; Meijers JC; van der Poll T
    J Immunol; 2005 Nov; 175(10):6764-71. PubMed ID: 16272333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
    Mook-Kanamori BB; Valls Serón M; Geldhoff M; Havik SR; van der Ende A; Baas F; van der Poll T; Meijers JC; P Morgan B; Brouwer MC; van de Beek D
    J Thromb Haemost; 2015 Nov; 13(11):2076-86. PubMed ID: 26340319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation.
    Hugenholtz GC; Meijers JC; Adelmeijer J; Porte RJ; Lisman T
    Thromb Haemost; 2013 May; 109(5):948-55. PubMed ID: 23467679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
    Shao Z; Nishimura T; Leung LL; Morser J
    J Thromb Haemost; 2015 Jun; 13(6):1090-102. PubMed ID: 25851247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system.
    Naito M; Taguchi O; Kobayashi T; Takagi T; D'Alessandro-Gabazza CN; Matsushima Y; Boveda-Ruiz D; Gil-Bernabe P; Matsumoto T; Chelakkot-Govindalayathil AL; Toda M; Yasukawa A; Hataji O; Morser J; Takei Y; Gabazza EC
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):646-53. PubMed ID: 23721130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
    Nagashima M; Yin ZF; Zhao L; White K; Zhu Y; Lasky N; Halks-Miller M; Broze GJ; Fay WP; Morser J
    J Clin Invest; 2002 Jan; 109(1):101-10. PubMed ID: 11781355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
    Qin L; D'Alessandro-Gabazza CN; Aoki S; Gil-Bernabe P; Yano Y; Takagi T; Boveda-Ruiz D; Ramirez Marmol AY; San Martin Montenegro VT; Toda M; Miyake Y; Taguchi O; Takei Y; Morser J; Gabazza EC
    J Thromb Haemost; 2010 Apr; 8(4):808-16. PubMed ID: 20088932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM; Taylor FB; Peer G; Bajzar L
    Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma.
    Fujiwara A; Taguchi O; Takagi T; D'Alessandro-Gabazza CN; Boveda-Ruiz D; Toda M; Yasukawa A; Matsushima Y; Miyake Y; Kobayashi H; Kobayashi T; Gil-Bernabe P; Naito M; Yoshida M; Morser J; Takei Y; Gabazza EC
    Lung; 2012 Apr; 190(2):189-98. PubMed ID: 22037793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
    Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
    J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
    Bouma BN; Mosnier LO
    Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):375-81. PubMed ID: 15692247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
    Toh CH
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
    Plug T; Meijers JC
    J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
    J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.
    Okumura N; Koh T; Hasebe Y; Seki T; Ariga T
    J Biol Chem; 2009 Jun; 284(24):16553-16561. PubMed ID: 19386599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
    Nagashima M; Yin ZF; Broze GJ; Morser J
    Front Biosci; 2002 Feb; 7():d556-68. PubMed ID: 11815293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
    Hayakawa M; Sawamura A; Gando S; Jesmin S; Naito S; Ieko M
    Thromb Res; 2012 Dec; 130(6):906-13. PubMed ID: 22353215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
    Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
    Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.